Celcuity Shares Drop Despite FDA Approval for Breast Cancer Drug
Despite receiving FDA approval for its breast cancer drug Revtorpyk (gedatolisib), Celcuity's stock fell approximately 15% as the company announced a delayed product launch planned for late Q3 2026, disappointing Wall Street analysts.
Tickers: $CELC